2篇
您的检索式：作者名="Yangsen Cao"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications显示文摘Objective:To validate the eighth edition of the AJCC staging system in patients with pancreatic adenocarcinoma receiving only stereotactic body radiation therapy and chemotherapy,and to propose modifications to improve prognostic accuracy.Methods:Patients with pathologically confirmed pancreatic adenocarcinoma without metastasis who were undergoing only chemoradiotherapy were included and staged according to the seventh and eighth editions of the AJCC staging system.Meanwhile,another group of stage T4 patients from the above enrollment with only portal vein involvement with or without tumor thrombi(PV±PVTT)were retrieved for survival comparisons.Modifications were proposed according to the survival comparisons.A cohort from the SEER database was used for external validation of the modified staging system.Results:A total of 683 patients were included.Patients with N2 or N1 but different T stages had significantly different survival outcomes according to the eighth edition.The survival of patients with(PV±PVTT)was comparable to that of patients with T4 tumors.The concordance index of the seventh and eighth editions,and the modified staging system was 0.744(95%CI:0.718—0.769),0.750(95%CI:0.725—0.775),and 0.788(95%CI:0.762-0.813),respectively.For external validation,the concordance index was 0.744(95%CI:0.718-0.770),0.750(95%CI:0.724-0.776),and 0.788(95%CI:0.762-0.814),respectively.Conclusions:The modified staging system is suggested to have the m ost accurate prognostic value.Hence,PV土PVTT should be added to the definition of T4 tumors regardless of tumor size.Patients with N2 or N1 in different T stages could be regrouped into different substages.Additionally,stage III should be subclassified into IIIA(T3N 2 and T4N 0)and IIIB(T4N 1-2). | Xiaofei Zhu Di Chen Yangsen Cao Xianzhi Zhao Xiaoping Ju Yuxin Shen Fei Cao Shuiwang Qing Fang Fang Zhen Jia Huojun Zhang | 2020 | Cancer Biology & Medicine2020，17，2： | 1 |
| 2 | Engineering biocompatible TeSex nano-alloys as a versatile theranostic nanoplatform显示文摘Photothermal nanotheranostics, especially in the near infrared II(NIR-II) region, exhibits a great potential in precision and personalized medicine, owing to high tissue penetration of NIR-II light.NIR-II-photothermal nanoplatforms with high biocompatibility as well as high photothermal effect are urgently needed but rarely reported so far. Te nanomaterials possess high absorbance to NIR-II light but also exhibit high cytotoxicity, impeding their biomedical applications. In this work, the controllable incorporation of biocompatible Se into the lattice of Te nanostructures is proposed to intrinsically tune their inherent cytotoxicity and enhance their biocompatibility, developing TeSe_(x) nano-alloys as a new kind of theranostic nanoplatform. We have uncovered that the cytotoxicity of Te nanomaterials primarily derives from irreversible oxidation stress and intracellular imbalance of organization and energy, and can be eliminated by incorporating a moderate proportion of Se(x = 0.43). We have also discovered that the as-prepared TeSe_(x) nano-alloys have extraordinarily high NIR-II-photothermal conversion efficiency(77.2%),^(64)Cu coordination and computed tomography contrast capabilities, enabling high-efficacy multimodal photothermal/photoacoustic/positron emission tomography/computed tomography imaging-guided NIR-II-photothermal therapy of cancer. The proposed nano-alloying strategy provides a new route to improve the biocompatibility of biomedical nanoplatforms and endow them with versatile theranostic functions. | Xiang Ling Zhaokui Jin Qi Jiang Xiaotao Wang Bin Wei Zhongchang Wang Yangsen Xu Tianye Cao Jonathan W.Engle Weibo Cai Chenliang Su Qianjun He | 2021 | National Science Review2021，8，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员